Caribou Biosciences (CRBU) Current Assets (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Current Assets data on file, last reported at $122.4 million in Q1 2026.

• Quarterly Current Assets fell 43.69% year-over-year to $122.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122.4 million (down 43.69% YoY) and the FY2025 annual result came in at $145.2 million, down 33.8% from the prior year.
• Current Assets fell to $122.4 million in Q1 2026 per CRBU's latest filing, from $145.2 million in the prior quarter.
• Across five years, Current Assets topped out at $368.0 million in Q1 2022 and bottomed at $122.4 million in Q1 2026.
• The 5-year median for Current Assets is $260.2 million (2022), against an average of $255.9 million.
• The widest annual swing landed in 2022, when Current Assets surged 146.86%; it then plunged 43.69% in 2026.
• Tracing CRBU's Current Assets over 5 years: stood at $260.2 million in 2022, then surged by 30.2% to $338.8 million in 2023, then sank by 35.26% to $219.4 million in 2024, then sank by 33.8% to $145.2 million in 2025, then dropped by 15.73% to $122.4 million in 2026.
• Per Business Quant, the three latest CRBU Current Assets figures stand at $122.4 million (Q1 2026), $145.2 million (Q4 2025), and $155.5 million (Q3 2025).

Peer Comparison